Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Highly Accessed Open Badges Research

The distinct expression patterns of claudin-10, -14, -17 and E-cadherin between adjacent non-neoplastic tissues and gastric cancer tissues

Man Gao1, Wei Li1, Haiming Wang2 and Guanjun Wang1*

Author Affiliations

1 Cancer Center, the First Hospital of Jilin University, Changchun, Jilin, China

2 Urinary surgery department, the First Hospital of Jilin University, Changchun, Jilin, China

For all author emails, please log on.

Diagnostic Pathology 2013, 8:205  doi:10.1186/1746-1596-8-205

The electronic version of this article is the complete one and can be found online at:

Received:22 October 2013
Accepted:28 November 2013
Published:10 December 2013

© 2013 Gao et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.



Recent data indicate that the cell adhesion proteins are abnormally regulated in several human cancers and the expression of the cell adhesion proteins E-cadherin and claudin proteins is involved in the etiology and progression of cancer. It is clear that these protein represent promising targets for cancer detection, diagnosis, and therapy.


To explore the expression distinction of the cell adhesion proteins claudin-10,-14,-17 and E-cadherin in the adjacent non-neoplastic tissues and gastric cancer tissues, 50 gastric cancer tissues and 50 samples of adjacent non-neoplastic tissues adjacent to the tumors were examined for expression of claudin-10,-14,-17 and E-cadherin by streptavidin-perosidase immunohistochemical staining method.


The positive expression rates of E-cadherin in gastric cancer tissues and adjacent non-neoplastic tissues were 32% and 74% respectively (P < 0.01). The positive expression rates of claudin-10 in gastric cancer tissues and adjacent non-neoplastic tissues were 24% and 72% respectively (P < 0.01). The positive expression rates of claudin-17 in gastric cancer tissues and adjacent non-neoplastic tissues were 18% and 70% (P < 0.01). In contrast, the positive expression rates of claudin-14 in gastric cancer tissues and adjacent non-neoplastic tissues were 58% and 24% respectively (P = 0.015 < 0.05) Thus in our study, the expression of E-cadherin, claudin-10, and claudin-17 was down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated. Correlations between claudins and E-cadherin expression with lymphatic metastasis were observed.


Our study reveals that the expression of E-cadherin, claudin-10, and claudin-17 were down-regulated in gastric cancer tissue while the expression of claudin-14 was up-regulated and correlation between claudins and E-cadherin expression with lymphatic metastasis were observed.

Virtual slides

The virtual slide(s) for this article can be found here: webcite.

Gastric cancer; Cell adhesion; Tight junction; Claudin-10; Claudin-14; Claudin-17; E-cadherin; Immunohistochemistry


Cell-cell adhesion junction is an essential necessity during cell differentiation, tissue development, and tissue homeostasis [1]. It is reported that the development of malignant tumors, in particular the transition from benign lesions to invasive, metastatic cancer, is characterized by a tumor cell’s ability to overcome cell-cell adhesion and to invade surrounding tissue and loss of cell-cell adhesion is displayed in many cancers and correlates with metastasis and poor prognosis [2]. Many different cell-adhesion molecules are implicated in human carcinogenesis [3]. During the transition from normal cells to highly malignant tumor cells, the expression of some of these adhesion molecules is switched off, whereas that of others is induced. E-cadherin, a transmembrane adhesion protein, is the major constituents of the epithelial cell junction system [4]. Besides E-cadherin exerts a potent invasion-suppressing role in tumor cell lines and in in vivo tumor model systems and loss of E-cadherin expression during tumor progression has been observed in numerous human carcinomas [5]. It is revealed that DNA hypermethylation and chromatin rearrangements within the regulatory regions of the E-cadherin gene have been correlated with the loss of E-cadherin expression in primary hepatocellular and breast carcinomas [6-8]. Other observations suggest that the loss of E-cadherin transcription in cancer cells is primarily due to transacting pathways regulating E-cadherin gene expression [9,10]. Besides supporting cell-cell adhesion, E-cadherin can affect a wide range of cellular functions that include activation of cell signaling pathways, regulation of the cytoskeleton and control of cell polarity [11-13].

Tight junctions, together with adherent junctions and desmosomes, form the apical junction complex in epithelial and endothelial cellular sheets [14-16]. The claudin protein family have a crucial role in formation of tight junctions (TJs), and consists of approximately 27 members, which are expressed with a tissue-specific distribution [17]. Because of the ability of tight junction proteins to recruit signaling proteins, tight junctions have also been hypothesized to be involved in the regulation of proliferation, differentiation, and other cellular functions [18,19]. Malignant cells not only accompanied with cell-adhesion abnormity but also frequently display structural and functional disruption of the tight junctions [20]. Recently, the abnormal expression of members of the claudin protein family has been reported to participate in tumorigenesis [21,22]. In particular, claudin-3 and claudin-4 are frequently overexpressed in several neoplasias, including ovarian, breast, pancreatic, and prostate cancers [23]. Moreover, claudin-4 protein is significantly up-regulated in breast invasive ductal carcinomas and is an important correlate with lymphatic metastasis [24]. Although the exact roles of these proteins in tumorgenesis are still being uncovered, it appears that claudin expression has significance during tumor progression [25]. Claudin-5 has been seen in a proportion of gastric carcinomas and seemed to be positively associated with biological markers associated with tumor growth, such as proliferation and apoptosis [26]. It is clear that they represent promising targets for cancer detection, diagnosis, and therapy.

In general, expression of different claudins has not been extensively studied in human tissues and in tumors [27]. An early study in the field showed that occludin was often down-regulated in gastrointestinal tumors [28] and claudin-10 has been found to be reduced in breast cancer as well as in colon cancer [29]. Besides, loss of claudin-17 appears to be associated with a more aggressive behavior of breast carcinoma [30]. These reports of decreased tight junction protein expression in cancer are consistent with the generally accepted idea that tumorigenesis is accompanied by a disruption of tight junctions, a process that may play an important role in the loss of cohesion, invasiveness, and lack of differentiation observed in cancer cells. In addition to the up-regulation or down-regulation of protein levels, phosphorylation of tight junction proteins, including claudins, may affect tight junction function in cancer. Interestingly, phosphorylation of claudin-3 and claudin-4 in ovarian cancer cells has been shown to disrupt tight junctions [31,32]. Paradoxically, other studies have shown that certain claudin proteins are up-regulated in cancer. Overexpression of claudin-3 and -4 has been shown in ovarian carcinoma [33]. In addition, claudin-3 and claudin-4 have also been reported to be expressed in other cancers, such as prostate, and pancreatic cancers [34].

It has been reported that the expression of claudin-2 and claudin-6 was reduced whereas the expression of claudin-11 in gastric cancer was increased in comparison with gastric adjacent non-neoplastic tissues [35]. Claudin-18 gene and claudin-23, frequently down-regulated in intestinal-type gastric cancer and has been shown to have prognostic value in gastric cancer [36]. In summary, in gastric cancer, claudin protein expression has been demonstrated to be of great importance and a relevant area for further study. It is revealed that E-cadherin is specifically required for tight junction formation, but not desmosome, and this appears to involve signaling rather than cell contact formation [37]. Thus, the objective of this study was to examine the expression of claudin-10,-14, -17 and E-cadherin in gastric carcinoma and adjacent tissue which have been less well studied. We used immunohistochemical staining to explore the expression of these proteins in gastric cancer and adjacent non-neoplastic tissues, and correlated the expression of these proteins with tumor differentiation and stage.

Materials and methods


There were 50 cases of gastric cancer and 50 cases of histologically normal adjacent non-neoplastic tissues taken out at more than 2 cm from the tumors were collected from patients being treated at the First Hospital of Jilin University during the period between August 2011 and May 2012. The patients’ medical records were reviewed to determine their age and gender. Sections of the primary tumor were analyzed to identify the histological grade, and the presence or absence of regional lymph node metastasis. There were 34 men and 16 women with average age of 49 years. The cases consisted of 14 well differentiated, 25 moderately differentiated and 11 poor differentiated histological appearance tumors. For the use of these clinical materials for research purposes, prior patient’s consent and approval from the Institute Research Ethics Committee was obtained. All the cancer cases were classified and graded according to the International Union against Cancer (UICC) staging system for gastric cancer.


Rabbit monoclonal antihuman E-Cadherin antibody (ab40772), Rabbit polyclonal to claudin-10 antibody (ab66053), Goat polyclonal to claudin-14 antibody (ab115868), Rabbit polyclonal to claudin-17 antibody(ab23333) were purchased from Abcam Technology (USA) and an streptavidin-perosidase immunohistochemistry reagent kit were purchased from Maixin Biology (Fujian, China).

Criteria for the positive claudin-10,-14 -17 and E-cadherin expression in tissue

The cells positively expressing claudin-10, -14 -17 and E-cadherin were identified by brown staining of cell membrane after reaction with claudin-10, -14,-17 and E-cadherin antibody. The claudin-10,-14,-17 positive tissues were quantified based on the percentage of positive cells which were serially counted in one microscopic field. The cell counting was repeated in five randomly-selected microscopic fields at × 400 magnification. The E-cadherin negative group contained less than 15% positive cells and the positive group, more greater than 15%. The claudin-10 negative groups were defined as a field with level less than 10% (of the tumor cells); positive groups had more than 10% positive cells. The claudin-14 negative group had less than 10% stained cells and the positive group more than 10%. The claudin-17 negative group contained less than 20% positive cells and the positive group, more greater than 20%.

Statistical analysis

The Chi-square test/Chi-Square Goodness-of-Fit Test was used to determine the prognostic significance value for disease progression of each factor alone, using a P-value < 0.05 for statistically significant associations. All the data were analyzed using SPSS 12.0 statistical software.


Population and tumor characteristics

The clinicopathological characteristics of the patients are summarized in Table 1.

Table 1. Expression of E-cadherin and clinicopathological characteristics in gastric cancer patients

The expression of claudin-10, claudin-17 and E-cadherin was reduced in gastric cancer

In our study, E-cadherin expression was evaluated in the membranes of 50 gastric cancers tissues and 50 specimens containing gastric tissue adjacent to the carcinoma. Positive expression of E-cadherin protein was found in 32.0% (16/50) of gastric carcinoma tissues and in 74% (37/50) of adjacent tissues (Table 1). The expression of E-cadherin in gastric cancer tissues was significantly lower than in adjacent tissues (The Chi-square test/Chi-Square Goodness-of-Fit Test, P < 0.01) (Figure 1A, B). As shown in Table 1 the expression of E-cadherin was not correlated with age (P =1.000), sex (P =0.494), expression of Ki 67 (P =0.356) but correlated with histological grade (P < 0.01) and lymph node metastasis (P < 0.01).

thumbnailFigure 1. Immunohistochemical demonstration of claudins protein and E-cadherin expression in human gastric cancer and adjacent tissue. Claudins and E-cadherin were expressed in the cell membrane. (A), high E-Cadherin expression was detected in tissue adjacent to human gastric cancer compared with low E-Cadherin expression in human gastric cancer tissue (B) (400×) (C), claudin-10 was highly expressed in epithelial cells adjacent to gastric cancer but was expressed at low levels in cancer tissue itself (D). (E), the low expression of claudin-14 in tissue adjacent to human gastric cancer compared to strong expression of claudin-14 in human gastric cancer tissue (F). (G), high claudin-17 expression was detected in tissue adjacent to human gastric cancer compared with low claudin-17 expression in human gastric cancer tissue (H) (400×).

Positive expression of claudin-10 protein was found in 24.0% (12/50) of gastric carcinoma tissues and in 72% (36/50) of adjacent tissues (Table 2). The expression of claudin-10 in gastric cancer tissues was significantly lower than in adjacent tissues (The Chi-square test/Chi-Square Goodness-of-Fit Test, P < 0.01) (Figure 1C, D). As shown in Table 2 the expression of claudin-10 was not correlated with age (P =1.000), sex (P =0.664), histological grade (P = 1.000), expression of Ki 67(P =0.464) but correlated with lymph node metastasis (P < 0.01) and expression of E-cadherin (P < 0.01).

Table 2. Expression of CLAUDIN-10, CLAUDIN-14, CLAUDIN-17 and clinic pathological characteristics in gastric cancer patients

Positive expression of claudin-17 protein was found in 18.0% (9/50) of gastric cancer tissues and in 70.0% (35/70) of adjacent tissues (Table 2). The expression rate of claudin-17 in gastric cancer tissues was lower than the rate in adjacent tissues (The Chi-square test/Chi-Square Goodness-of-Fit Test, P < 0.01) (Figure 1G, H). As shown in Table 2 the expression of claudin-17 was not correlated with age (P =0.677), sex (P =0.475), histological grade (P = 1.000), expression of Ki 67(P =0.633) lymph node metastasis (P < 0.05) but correlated with expression of E-cadherin (P < 0.01).

The expression of claudin-14 was increased in gastric cancer

The membrane staining of claudin-14 was strong in gastric cancer tissues and weak in adjacent tissues. Claudin-14 was expressed in 58.0% (29/50) of gastric cancer tissues. Cells were positive for claudin-14 in 24.0% (12/50) of tissues adjacent to the cancer. We conclude that claudin-14 expression is significantly higher (Figure 1E, F) in gastric cancer samples than in histologically normal gastric tissue. (The Chi-square test/Chi-Square Goodness-of-Fit Test, P < 0.01). As shown in Table 2 the expression of claudin-17 was not correlated with age (P =1.000), sex (P =0.355), histological grade (P = 0.641), expression of Ki 67 (P =1.000) but correlated with lymph node metastasis (P < 0.01) and negatively related with expression of E-cadherin (P < 0.05).

Claudin-10, and claudin-14 were concurrently expressed in gastric cancer

We investigated the correlation between claudin-10, claudin-14 and claudin-17 expression using The Chi-square test/Chi-Square Goodness-of-Fit Test. Although we find a correlation between claudin-17 and claudin-10 (The Chi-square test/Chi-Square Goodness-of-Fit Test, φ = 0.693, P <0.01) or with claudin-14 (The Chi-square test/Chi-Square Goodness-of-Fit Test, φ = 0.124, P = 0.695), we have not find that the expression of claudin-10 correlated with the expression of claudin-14 (The Chi-square test/Chi-Square Goodness-of-Fit Test, φ =0.164, P = 0.516). The detailed results of the analysis are described in Table 3.

Table 3. Correlation between the expression of claudin-10, claudin-14 and claudin-17


The majority of human cancers originate from epithelial cells. Normally, epithelial cells are tightly interconnected through several junction structures, including tight junctions, adherents-type junctions and desmosomes, which are intimately associated with the actin and intermediate cytoskeleton. Including carcinomas of the breast, colon, prostate, liver, skin, kidney and lung appear to cause the loss of E-cadherin function, caused by several different mechanisms including deletion or mutational inactivation of the E-cadherin gene [38]. Notably, mutations in the E-cadherin gene are evident in cases of familial gastric cancers, which indicates that mutation of the E-cadherin gene is sufficient to predispose individuals to the development of malignant cancer. Moreover, the loss of E-cadherin impair E-cadherin-mediated cell-cell adhesion and E-cadherin contributes to epidermal barrier formation by regulating the incorporation of claudins into tight junctions and is specifically required for correct tight junction formation [39].

Although the normal ratio of claudin proteins has a role in maintaining the structure and function of tight junctions in epithelial cells, the mechanisms by which claudins expression and destruction of tight junctions induce tumor formation and the effect of these changes on tumor progression have not been studied in detail [40]. It has been postulated that both abnormal expression and phosphorylation of claudin proteins would cause the structural and functional disruption of tight junctions [41]. Currently, it is reported that the alternation of claudins expression is one of the mechanisms responsible for loss of cell adhesion, altered polarity, poor differentiation and increased invasive potential of neoplastic cells [42]. In this study, expression of claudin-10, 14, 17 and was studied in 50 cases of gastric carcinoma and adjacent non-neoplastic tissues adjacent to the gastric carcinoma tissues. The results show variable and heterogenous expression of claudin-10, -14 and-17 in gastric carcinoma. The most prominent expression of claudins was seen for claudins-14, where about 58% of cases showed positivity, whereas expression was weaker for claudin-10, which showed 24% of cases positive, and for claudin-17, which showed 18% of cases positive. In accordance with this, we also observed lower E-cadherin expression in diffuse carcinomas. It might also be that loss of claudins and E-cadherin expression is somehow interrelated in as much as E-cadherin has been shown to influence the formation of tight junctions and desmosomes although it mainly mediates the assembly of adherents junctions. In line with this, there was an association between expression of claudins-4 and -5 and E-cadherin [43]. However, little data are available on the functional association between E-cadherin and claudins at present. Several proteins were identified that were associated with prognosis of the gastric cancer patients, for instance, It is reported that Astragalus saponins inhibited human gastric cancer cell growth, decreased the invasion ability and induced the apoptosis and Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients [44,45]. In addition to this, inducible nitric oxide synthase expression in gastric adenocarcinoma related with lymph angiogenesis and lymphatic metastasis and the expression of TIMP3 gene may provide evidence for the molecular diagnosis and stage evaluation of gastric cancer [46,47]. Our data revealed that E-cadherin expression has been associated with a poorer prognosis of the patients. In general, such an association could not be seen with claudins, except for claudin-3, where its lowered expression was associated with a marginally poorer prognosis [48].

In conclusion, our present data observes tight junction proteins claudins-10, -14, -17 and E-cadherin between human gastric cancers and adjacent non-neoplastic tissues correlate with lymph node metastasis. In addition, claudin-10, claudin-17 and E-cadherin. In this respect, the loss of the claudin-10 and claudin-17 may resemble E-cadherin and together with this molecule, might contribute to the loose cell cohesion in gastric cancer.


The present work infers that the expression altered of claudin-10, claudin-14, claudin-17 and E-cadherin between human gastric cancers and adjacent non-neoplastic tissues correlate with lymph node metastasis. In addition, claudin-10, claudin-17 and E-cadherin were concurrently expressed in gastric cancer. However, the specific mechanism responsible for these observations needs to be addressed in the future.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

GW carried out part of experiments, participated in the design of the study, performed the statistical analysis, and drafted the manuscript. MG and WL carried out most of experiments, and helped draft the manuscript. HW assisted with the experiments, and helped to edit the paper. All authors have read and approved the final manuscript.


  1. Lee M, Vasioukhin V: Cell polarity and cancer–cell and tissue polarity as a non-canonical tumor suppressor.

    J Cell Sci 2008, 121:1141-1150. PubMed Abstract | Publisher Full Text OpenURL

  2. Friedl P, Wolf K: Tumour-cell invasion and migration: diversity and escape mechanisms.

    Nat Rev Cancer 2003, 3:362-374. PubMed Abstract | Publisher Full Text OpenURL

  3. Johnson JP: Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease.

    Cancer Metastasis Rev 1991, 10:11-22. PubMed Abstract | Publisher Full Text OpenURL

  4. Christofori G, Semb H: The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene.

    Trends Biochem Sci 1999, 24:73-76. PubMed Abstract | Publisher Full Text OpenURL

  5. Berx G, Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression.

    Breast Cancer Res 2001, 3:289-293. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  6. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion system in human cancers.

    Am J Pathol 1998, 153:333-339. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  7. Wilson AS, Power BE, Molloy PL: DNA hypomethylation and human diseases.

    Biochim Biophys Acta 2007, 1775:138-162. PubMed Abstract | Publisher Full Text OpenURL

  8. Szyf M, Pakneshan P, Rabbani SA: DNA methylation and breast cancer.

    Biochem Pharmacol 2004, 68:1187-1197. PubMed Abstract | Publisher Full Text OpenURL

  9. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D, Van Roy F: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.

    Mol Cell 2001, 7:1267-1278. PubMed Abstract | Publisher Full Text OpenURL

  10. Oloumi A, McPhee T, Dedhar S: Regulation of E-cadherin expression and β-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochimica et Biophysica Acta (BBA)-Molecular.

    Cell Res 2004, 1691:1-15. OpenURL

  11. Provost E, Rimm DL: Controversies at the cytoplasmic face of the cadherin-based adhesion complex.

    Curr Opin Cell Biol 1999, 11:567-572. PubMed Abstract | Publisher Full Text OpenURL

  12. Yap AS, Brieher WM, Gumbiner BM: Molecular and functional analysis of cadherin-based adherens junctions.

    Annu Rev Cell Dev Biol 1997, 13:119-146. PubMed Abstract | Publisher Full Text OpenURL

  13. Halbleib JM, Nelson WJ: Cadherins in development: cell adhesion, sorting, and tissue morphogenesis.

    Genes Dev 2006, 20:3199-3214. PubMed Abstract | Publisher Full Text OpenURL

  14. Niessen CM: Tight junctions/adherens junctions: basic structure and function.

    J Invest Dermatol 2007, 127:2525-2532. PubMed Abstract | Publisher Full Text OpenURL

  15. Dejana E: Endothelial cell–cell junctions: happy together.

    Nat Rev Mol Cell Biol 2004, 5:261-270. PubMed Abstract | Publisher Full Text OpenURL

  16. Tsukita S, Yamazaki Y, Katsuno T, Tamura A: Tight junction-based epithelial microenvironment and cell proliferation.

    Oncogene 2008, 27:6930-6938. PubMed Abstract | Publisher Full Text OpenURL

  17. Zhang GH, Wu L, Yu GY: Tight junctions and paracellular fluid and ion transport in salivary glands.

    Chin J Dent Res 2012, 16:13-46. OpenURL

  18. Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy.

    Cancer Res 2005, 65:9603-9606. PubMed Abstract | Publisher Full Text OpenURL

  19. Fanning AS, Anderson JM: PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane.

    J Clin Invest 1999, 103:767-772. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  20. Lee H, Seo J, Nam J-M, Char K: Nanoparticle-functionalized polymer platform for controlling metastatic cancer cell adhesion, shape, and motility.

    ACS Nano 2011, 5:5444-5456. PubMed Abstract | Publisher Full Text OpenURL

  21. Günzel D, Alan S: Claudins and the modulation of tight junction permeability.

    Physiol Rev 2013, 93:525-569. PubMed Abstract | Publisher Full Text OpenURL

  22. Turksen K, Troy T-C: Barriers built on claudins.

    J Cell Sci 2004, 117:2435-2447. PubMed Abstract | Publisher Full Text OpenURL

  23. Mullin J: Epithelial barriers, compartmentation, and cancer.

    Sci Signal 2004, 2004:pe2. OpenURL

  24. Van Itallie C, Rahner C, Anderson JM: Regulated expression of claudin-4 decreases paracellular conductance through a selective decrease in sodium permeability.

    J Clin Invest 2001, 107:1319-1327. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  25. Coradini D, Casarsa C, Oriana S: Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment.

    Acta Pharmacol Sin 2011, 32:552-564. PubMed Abstract | Publisher Full Text OpenURL

  26. Oliveira S, Morgado-Diaz J: Claudins: multifunctional players in epithelial tight junctions and their role in cancer.

    Cell Mol Life Sci 2007, 64:17-28. PubMed Abstract | Publisher Full Text OpenURL

  27. Dhawan P, Singh AB, Deane NG, No Y, Shiou S-R, Schmidt C, Neff J, Washington MK, Beauchamp RD: Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer.

    J Clin Invest 2005, 115:1765-1776. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  28. Saitou M, Furuse M, Sasaki H, Schulzke J-D, Fromm M, Takano H, Noda T, Tsukita S: Complex phenotype of mice lacking occludin, a component of tight junction strands.

    Mol Biol Cell 2000, 11:4131-4142. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  29. Hewitt KJ, Agarwal R, Morin PJ: The claudin gene family: expression in normal and neoplastic tissues.

    BMC Cancer 2006, 6:186. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  30. Tőkés A-M, Szász AM, Juhász É, Schaff Z, Harsányi L, Molnár IA, Baranyai Z, Besznyák I Jr, Zaránd A, Salamon F: Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry.

    Pathol Oncol Res 2012, 18:593-606. PubMed Abstract | Publisher Full Text OpenURL

  31. D’Souza T, Agarwal R, Morin PJ: Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells.

    J Biol Chem 2005, 280:26233-26240. PubMed Abstract | Publisher Full Text OpenURL

  32. D’Souza T, Indig FE, Morin PJ: Phosphorylation of claudin-4 by PKCϵ regulates tight junction barrier function in ovarian cancer cells.

    Exp Cell Res 2007, 313:3364-3375. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  33. Rangel LB, Agarwal R, D’Souza T, Pizer ES, Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, Morin PJ: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.

    Clin Cancer Res 2003, 9:2567-2575. PubMed Abstract | Publisher Full Text OpenURL

  34. Long H, Crean CD, Lee W-H, Cummings OW, Gabig TG: Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.

    Cancer Res 2001, 61:7878-7881. PubMed Abstract | Publisher Full Text OpenURL

  35. Lin Z, Zhang X, Liu Z, Liu Q, Wang L, Lu Y, Liu Y, Wang M, Yang M, Jin X: The distinct expression patterns of claudin-2,-6, and - 11 between human gastric neoplasms and adjacent non-neoplastic tissues.

    Diagn Pathol 2013, 8:1-7. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  36. Ohtsuki S, Yamaguchi H, Katsukura Y, Asashima T, Terasaki T: mRNA expression levels of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting.

    J Neurochem 2008, 104:147-154. PubMed Abstract | Publisher Full Text OpenURL

  37. Tunggal JA, Helfrich I, Schmitz A, Schwarz H, Günzel D, Fromm M, Kemler R, Krieg T, Niessen CM: E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions.

    EMBO J 2005, 24:1146-1156. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  38. Berx G, Becker KF, Höfler H, Van Roy F: Mutations of the human E-cadherin (CDH1) gene.

    Hum Mutat 1998, 12:226-237. PubMed Abstract | Publisher Full Text OpenURL

  39. Henijink IH, Brandenburg SM, Noordhoek JA, Postma DS, Slebos D-J, Van Oosterhout AJ: Characterisation of cell adhesion in airway epithelial cell types using electric cell–substrate impedance sensing.

    Eur Respir J 2010, 35:894-903. PubMed Abstract | Publisher Full Text OpenURL

  40. Shin K, Fogg VC, Margolis B: Tight junctions and cell polarity.

    Annu Rev Cell Dev Biol 2006, 22:207-235. PubMed Abstract | Publisher Full Text OpenURL

  41. Furuse M, Tsukita S: Claudins in occluding junctions of humans and flies.

    Trends Cell Biol 2006, 16:181-188. PubMed Abstract | Publisher Full Text OpenURL

  42. Martin TA, Jiang WG: Loss of tight junction barrier function and its role in cancer metastasis.

    Biochim Biophys Acta 2009, 1788:872-891. PubMed Abstract | Publisher Full Text OpenURL

  43. Soini Y, Tommola S, Helin H, Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype.

    Virchows Arch 2006, 448:52-58. PubMed Abstract | Publisher Full Text OpenURL

  44. Wang T, Xuan X, Li M, Gao P, Zheng Y, Zang W, Zhao G: Astragalus saponins affect proliferation, invasion and apoptosis of gastric cancer BGC-823 cells.

    Diagn Pathol 2013, 8:179. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  45. Zhang G, Qu Y, Dang S, Yang Q, Shi B, Hou P: Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients.

    Diagn Pathol 2013, 8:173. PubMed Abstract | BioMed Central Full Text OpenURL

  46. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S, Xie XJ: Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features.

    BMC Cancer 2002, 2:8. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  47. Guan Z, Zhang J, Song S, Dai D: Promoter methylation and expression of TIMP3 gene in gastric cancer.

    Diagn Pathol 2013, 8:110. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  48. Shang X, Lin X, Alvarez E, Manorek G, Howell SB: Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

    Neoplasia 2012, 14:974. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL